6 new drugs in shortage

Advertisement

Active U.S. drug shortages stood at 225 at the end of the third quarter, similar to the past three quarters, according to the American Society of Health-System Pharmacists. The 87 new shortages reported through September nearly equal the 89 reported for all of 2025, and chemotherapy shortages in particular have outlasted drugmakers’ resupply estimates. The FDA’s database continues to reflect new discontinuations weekly.

Here are six recent shortage and discontinuation listings, according to the FDA database:

  1. Bendamustine hydrochloride injection: Eagle Pharmaceuticals is discontinuing its 100-milligram/4-milliliter Belrapzo injection as a business decision, the FDA said Nov. 13.
  1. Propranolol hydrochloride extended-release capsules: Teva Pharmaceuticals is discontinuing manufacture of its 60-milligram, 80-milligram, 120-milligram and 160-milligram capsules, the FDA said Nov. 13.
  1. Somatropin injection: Ferring Pharmaceuticals is discontinuing manufacture of its Zomacton injection, the FDA said Nov. 13. Novo Nordisk discontinued its Norditropin 30-milligram/3-milliliter injection a year ago.
  1. Valrubicin solution: Endo Operations is discontinuing manufacture of Valstar preservative-free 40-milligram/1-milliliter solution, the FDA said Nov. 13.
  1. Lincomycin hydrochloride injection: Pfizer is discontinuing manufacture of its Lincocin 10-milliliter multiple-dose vial, the FDA said Nov. 6. Pfizer discontinued the 2-milliliter vial in February, and XGen Pharmaceuticals discontinued its lincomycin vials in March as a business decision.
  1. Tadalafil tablets: Eli Lilly is discontinuing manufacture of Adcirca 20-milligram tablets, the FDA said Nov. 5.
Advertisement

Next Up in Pharmacy

Advertisement